Targeting prostate cancer with specialized CAR-T cells
Official title: Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy
Funded at Sloan-Kettering Inst Can Research · NIH-10898319 · Data updated 2026-11-12
This study is testing a new type of CAR-T cell therapy for men with neuroendocrine prostate cancer, aiming to create a treatment that can better target the cancer as it changes, using special cells that can find and attack the tumors more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 4, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $720,416 |
| NIH project number | 1R01CA287491-01A1 |
| Project ID | NIH-10898319 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with neuroendocrine prostate cancer, particularly those with castrate-resistant disease.
✕Less likely to help
Patients with other types of prostate cancer or those who do not express the targeted antigens DLL3 and PSMA may not benefit from this research.
What this research studies
This research aims to develop a new type of CAR-T cell therapy specifically designed to target neuroendocrine prostate cancer (NEPC), which often shows varied antigen expression. The approach focuses on using bi-specific CAR-T cells that can recognize both DLL3 and PSMA antigens, which change as the cancer progresses. By utilizing advanced imaging techniques, the therapy seeks to effectively deliver these CAR-T cells to the cancer sites, ensuring they can survive and function properly in the challenging environment of metastatic tumors. The research builds on previous successes in treating blood cancers and aims to adapt these strategies for solid tumors like NEPC.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with neuroendocrine prostate cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results using CAR-T cell therapies in hematologic malignancies, but this approach for solid tumors like NEPC is still being explored.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Ponomarev, Vladimir — Sloan-Kettering Inst Can Research
- Study coordinator: Ponomarev, Vladimir
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.